The US Food and Drug Administration (FDA), the government agency responsible for approving and regulating medical products, announced today its intent to study blockchain tech.
Revealed in press materials published by IBM Watson Health, the research initiative will find the FDA teaming with IBM to explore how data from electronic medical records, clinical trials and health data from wearable devices could be better shared and audited using a blockchain.
Initial tests will focus on clinical trials and real-world evidence data related to oncological data, according to the statements.
Overall, the partners positioned the trial as one that could one day mitigate the potential of patient privacy breaches during electric exchanges.
The release reads:
According to the release, the IBM and the FDA will work together for two years, with the aim to publish their findings in 2017.
Food and drugs image via Shutterstock
The leader in news and information on cryptocurrency, digital assets and the future of money, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups. As part of their compensation, certain CoinDesk employees, including editorial employees, may receive exposure to DCG equity in the form of stock appreciation rights, which vest over a multi-year period. CoinDesk journalists are not allowed to purchase stock outright in DCG.